Factors affecting lower limb muscle strength and cardiopulmonary fitness after allogeneic hematopoietic stem cell transplantation.

PURPOSE: The aim of this study is to clarify the factors affecting physical function after allogeneic hematopoietic stem cell transplantation (HSCT).
METHODS: We retrospectively analyzed 88 patients (median age, 44.5 years) who received allogeneic HSCT. Leg extension torque and peak oxygen consumption (VO2) were evaluated before and after HSCT. Patient factors (age, sex, underlying diseases, hemoglobin, serum albumin, and Karnofsky performance status score before transplant) and transplant factors (conditioning regimen, days to neutrophil engraftment, grades of acute graft-versus-host disease [GVHD], infections, and the interval between pre- and post-evaluation) were collected via chart review, and were used for correlational and comparison analyses in order to identify the variables associated with reduced post-HSCT leg extension torque and peak VO2. Stepwise multiple regression analyses for post-HSCT leg extension torque and post-HSCT peak VO2 were performed using age, sex, and the related variables with a p value < 0.2 in the correlational and comparison analyses.
RESULTS: Leg extension torque and peak VO2 were significantly reduced after HSCT (p < 0.001). Pre-HSCT leg extension torque, grades of acute GVHD, age, and the interval between pre- and post-evaluation were identified as significant factors associated with reduced post-HSCT leg extension torque. However, none of these factors were significantly associated with reduced post-HSCT peak VO2, and only its pre-transplant value was identified as a significant factor.
CONCLUSIONS: These findings suggest that improvements in muscle strength and cardiopulmonary fitness before HSCT are crucial for maintaining post-treatment physical function, especially in elderly individuals with acute GVHD requiring a long-term stay in a protective environment.

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative but intensive therapy for a variety of hematopoietic disorders, and the number of HSCTs has continued to increase over the last ten years, especially in the elderly population. The outcomes of HSCT have also improved and the number of recipients who achieve long-term survival after HSCT continues to increase. Therefore, the current goal of HSCT is not only curing disease but also maintaining a high quality of life while reducing physical and/or mental distress after HSCT [1-3].

Deconditioning and reduction of physical function are likely to occur after HSCT. Decreased physical activity due to isolation in a protective environment, and the impact of regimen-related toxicity and/or post-transplant complications have been reported as causes for this physical decline [4-6]. Decreases in endurance capacity may result in easy fatigability and loss of muscle strength may cause disabilities.

The purpose of exercise and rehabilitation for patients undergoing HSCT is to prevent deconditioning and recover from decreased physical function. Previous studies have shown the efficacy of rehabilitation in patients undergoing HSCT using a variety of exercise modalities, including aerobic, resistance, and mixed (aerobic and resistance) programs [7-16]. However, functional capacity declines after HSCT, even with exercise therapy [8, 10, 12, 17, 18]. Thus, identifying the factors related to physical function after HSCT is crucial to establish better preventive and rehabilitative strategies. Some studies have suggested that the decrease in fitness was associated with the fever period and total dose of corticosteroids [17], while the decrease in strength was associated with the total dose of corticosteroids [17, 18]. However, in these studies, the sample size was small [17], and a 6-min walk test was used for the evaluation of fitness [17, 18] instead of peak oxygen consumption (VO2) during cardiopulmonary exercise testing (CPX), which is the gold standard. In addition, certain important factors, such as baseline physical function before HSCT, were not included in these previous analyses [17, 18]. Thus, the aim of the present study was to explore the factors associated with post-HSCT leg extension muscle strength and cardiopulmonary fitness evaluated with peak VO2.

Methods

Study design

This was a retrospective cohort study performed at the Keio University Hospital in Tokyo, Japan. The study protocol was approved by the Ethics Committee of Keio University School of Medicine (No. 20120072).

Participants

Of 146 consecutive patients who underwent allogeneic HSCT from April 2008 to March 2013, 108 patients satisfied the inclusion and exclusion criteria. Inclusion criteria were aged 18 years or older on the day of HSCT, underwent allogeneic HSCT at Keio University Hospital, and were evaluated for leg extension muscle strength and/or cardiopulmonary fitness using CPX at both pre- and post-HSCT. Patients were excluded if they developed any severe physical dysfunctions that could affect muscular strength and fitness evaluation, such as joint contractures and/or severe joints pain of the lower extremities; avascular necrosis of the femur head; painful metastatic bone lesions; bone lesions requiring limited weight bearing; severe heart failure (New York Heart Association, III–IV); or required assistance for basic activities of daily living. Patients were also excluded from the study if they could not receive leg extension muscle strength and/or cardiopulmonary fitness evaluations due to acute somatic conditions (such as infection, fever, or acute bleeding) at the time of evaluation. After excluding these patients and those with missing data for the analyses, 88 patients were enrolled in the study.

Physical therapy

All patients participated in a rehabilitation program 5 days a week before, during, and after HSCT. At the rehabilitation gym, the patients received physical therapy including stretching of the neck, trunk, and extremities; resistance exercise for the muscles of the trunk and upper and lower extremities; aerobic exercise using a treadmill or cycle ergometer (up to 30 min) with an aim of approximately 60% of heart rate (HR) reserve calculated according to the Karvonen method [19]: (HRpeak during CPX − HRrest) × 60 %  + HRrest; and walking and stair training. An infrared ear/finger clip heart rate sensor was used for monitoring the heart rates during exercise. The content and intensity of the exercise were adjusted according to the physical condition of each patient. From the start of conditioning to neutrophil engraftment and other periods of neutropenia, such as those caused by additional chemotherapy before HSCT, a similar exercise program was carried out in the protective environment or the ward. However, during this period, walking tended to be more frequent than exercise on the ergometer and treadmill due to the patients’ physical conditions and lack of equipment. As such, the location of exercise was changed from the ward to the rehabilitation gym after HSCT when permission from the attending hematologists was obtained after achieving sustained neutrophil engraftment.

Treatment of acute graft-versus-host disease

Primary treatment of acute graft-versus-host disease (GVHD) was provided according to its grades [20]. Patients with grade I acute GVHD were treated with topical steroids. Patients with grade II–IV acute GVHD were treated with 1.0–2.0 mg/kg/day of (methyl-)prednisolone, while grade II acute GVHD limited to the skin was treated with hydrocortisone infusion and/or 0.5–1.0 mg/kg/day of (methyl-)prednisolone. Once patients responded, the dose of steroid started being tapered 10% of initial dose every 5 days.

Multidisciplinary team approaches

For all the participants, team conferences with multidisciplinary members including registered dieticians, psychiatrists, dentists, transplant coordinators, pharmacists, physical therapists, and physiatrists were held every week or once every 2 weeks.

Evaluation of strength and cardiopulmonary fitness

Muscle strength and cardiopulmonary fitness evaluations were performed on each patient twice: before the HSCT conditioning regimen (pre) and at the initiation of gym-based training when hematopoietic recovery was obtained after HSCT (post).

Leg extension muscle strength

To evaluate leg extension muscle strength, an isokinetic test of peak leg extension torque was performed with a recumbent cycle ergometer at 50 rpm (Strength Ergo 240™; Mitsubishi Electric Corporation, Tokyo, Japan). This test has excellent test-retest reliability and sufficient validity against a conventional isokinetic dynamometer [21, 22]. The backrest was adjusted to a reclining position (110°) and the seat position was adjusted so that the patient’s knee was flexed 20° when at maximal extension. The trunk of the body was fixed at the shoulders with seatbelts. The peak torque values for five revolutions were measured and averaged. Each patient performed the test twice and the higher value was adopted. The adopted peak leg extension torque was adjusted to a value per kg of body weight.

Cardiopulmonary fitness

The CPX was performed to the symptom-limited maximum using an upright, servo motor type, cycle ergometer (Strength Ergo 8™; Mitsubishi Electric Corporation, Tokyo, Japan). For each patient, breath-by-breath VO2 was measured during the cycling exercise at 60 rpm through a face mask using an expired gas analyzer (AE-300S™; Minato Medical Science Company Limited, Tokyo, Japan or Vmax 29™; SensorMedics Corporation, Yorba Linda, CA, USA). Both systems consist of a dumbbell type paramagnetic oxygen analyzer and infrared carbon dioxide analyzer, and both systems’ reliability and validity have been confirmed [23-26]. After 2 min of rest and 2 min of unloaded pedaling, the exercise load was increased by 10–15 W per min using a ramp protocol. Exercise was continued up to the limits of tolerance indicated by reduced pedaling rotation (despite being encouraged), unbearable shortness of breath, and/or a plateau in VO2 or HR response. Peak VO2 (mL/kg/min) was measured as the average value obtained during the last 30 s of the incremental test as an index of endurance capacity. Peak VO2 was adjusted to a value per kilogram of body weight for the analyses.

Data collection

Demographic information and clinical data were collected via the medical charts. Demographic data included age, sex, underlying diseases (leukemia, lymphoma, multiple myeloma, or aplastic anemia), conditioning regimen (myeloablative conditioning or reduced-intensity conditioning, total body irradiation, or non-total body irradiation), serum albumin level, hemoglobin level, and Karnofsky performance status (KPS) score [27] before HSCT. The interval between pre- and post-evaluation, number of days from HSCT to neutrophil engraftment, grades of acute GVHD [20], and infections (cytomegalovirus disease, bacterial infection, and invasive pulmonary aspergillosis) were also collected as clinical data.

Analyses

Descriptive analyses were performed on the patients’ characteristics. Pre- and post-differences for leg extension torque and peak VO2 were examined using a paired t test.

To clarify the factors related to leg extension torque and peak VO2 post-HSCT, we analyzed their relationships with several variables at baseline and during the clinical course via correlational analyses or comparison analyses. For continuous variables such as age, serum albumin level, and hemoglobin level, correlations between these variables and post-HSCT leg extension torque or post-HSCT peak VO2 were analyzed using the Pearson’s product moment correlation coefficient or the Spearman’s correlation coefficient, depending on the type of variable. With regard to the categorical variables such as sex and infectious complications, post-HSCT leg extension torque and post-HSCT peak VO2 were divided into two groups according to the category and were then compared using an independent t test.

Stepwise multiple regression analyses for post-HSCT leg extension torque and post-HSCT peak VO2 were performed using age, sex, and the variables with a p value < 0.2 in the above correlational or comparison analyses.

All statistical analyses were performed using IBM SPSS version 23 (IBM Corporation, Armonk, NY, USA), and a p value < 0.05 was considered to be statistically significant.

Results

Patients’ characteristics are shown in Table 1. Both leg extension torque and peak VO2 significantly decreased after HSCT (p < 0.001 for both; Fig. 1). Of note, peak VO2 was evaluated in 67 of the 88 patients at both pre- and post-HSCT; 12 patients pre-HSCT and 16 patients post-HSCT could not be evaluated due to poor general condition and/or limited time for evaluation.

Table 1

Patient characteristics (n = 88)

Age, years	44.5 (30–52)
Sex, male/female	46/42
Underlying diseases
Acute myeloid leukemia	17 (19.3)
Acute lymphoblastic leukemia	19 (21.6)
Myelodysplastic syndrome	12 (13.6)
Chronic myelogenous leukemia	5 (5.7)
Other leukemia	3 (3.4)
Myeloproliferative neoplasms	2 (2.3)
Aplastic anemia	8 (9.1)
Hodgkin/non-Hodgkin lymphoma	12 (13.6)
Multiple myeloma	10 (11.4)
Prior allogeneic HSCT (stem cell source and type of donor)
None	84 (95.5)
Bone marrow/PBSCs from an HLA-identical sibling	3 (3.4)
Bone marrow from an unrelated donor	1 (1.1)
Stem cell source and type of donor
Bone marrow/PBSCs from an HLA-identical sibling	21 (23.9)
Bone marrow from an HLA-mismatched family member	1 (1.1)
Bone marrow from an unrelated donor	59 (67.0)
Cord blood from an unrelated donor	7 (8.0)
Conditioning
Myeloablative	59 (67.0)
Reduced-intensity	29 (33.0)
Total body irradiation-based	64 (72.7)
Non-total body irradiation	24 (27.3)
Karnofsky performance status score before HSCT	100 (90–100)
Number of patients achieving engraftment	88 (100)
Grades of acute graft-versus-host disease
0	35 (39.8)
I	18 (20.5)
II	28 (31.8)
III	5 (5.7)
IV	2 (2.3)
Infections
Cytomegalovirus disease	16 (18.2)
Bacterial infection	54 (61.4)
Invasive pulmonary aspergillosis	4 (4.5)
Interval between pre- and post-transplant evaluation	69 (61–80)
Interval between pre-evaluation and transplantation	27 (25–30)
Interval between transplantation and post-evaluation	41 (33–50)
Length of hospital stay	121 (97–161)

Data are presented as median (interquartile range) or number (%)

HSCT hematopoietic stem cell transplantation, PBSC peripheral blood stem cell, HLA human leukocyte antigen

Fig. 1

Comparison of leg extension torque (a) and peak oxygen consumption (VO2) (b) pre- and post-hematopoietic stem cell transplantation (HSCT)

The post-HSCT values of both variables significantly decreased compared to the pre-HSCT values. Error bars indicate standard deviation

In the correlational or comparison analyses, variables with p < 0.2 were age, sex, serum albumin, pre-HSCT leg extension torque, pre-HSCT peak VO2, KPS score, pre- and post-evaluation interval, grades of acute GVHD, leukemia, aplastic anemia, cytomegalovirus disease, and invasive pulmonary aspergillosis for post-HSCT leg extension torque; and age, serum albumin, pre-HSCT leg extension torque, and pre-HSCT peak VO2 for post-HSCT peak VO2 (Tables 2 and 3). We included age, sex, and these variables with p < 0.2 in the multiple regression models. Multiple regression analysis for post-HSCT leg extension torque revealed that lower pre-HSCT leg extension torque, higher grades of acute GVHD, older age, and longer interval between pre- and post-evaluations were significant factors associated with reduced post-HSCT leg extension torque (Table 4(a)). Conversely, only lower pre-HSCT peak VO2 was significantly associated with reduced post-HSCT peak VO2 (Table 4(b)).

Table 2

Correlation coefficients between continuous variables and leg extension torque and peak VO2 post-hematopoietic stem cell transplantation

Variable		Post-HSCT
		Leg extension torque (n = 88)		Peak VO2 (n = 67)
		Correlation Coefficient	p value	Correlation Coefficient	p value
Pre-HSCT	Age, years	− 0.55	< 0.001	− 0.30	0.013
	Serum albumin, g/dL	0.16	0.131	0.19	0.127
	Hemoglobin, g/dL	− 0.08	0.444	− 0.06	0.648
	Leg extension torque, N·m/kg	0.71	< 0.001	0.32	0.008
	Peak VO2, mL/kg/min	0.24	0.038	0.50	< 0.001
	Karnofsky performance status score	0.14	0.181	0.05	0.695
Pre- and post-evaluation interval, days		− 0.37	< 0.001	0.07	0.578
Duration from HSCT to neutrophil engraftment, days		− 0.01	0.935	− 0.01	0.921
Grades of acute GVHD		− 0.35	0.001	0.04	0.972

VO oxygen consumption, HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease

Table 3

Comparison of variables and post-hematopoietic stem cell transplantation leg extension torque and peak VO2 via independent t test

	Post-HSCT
	Leg extension torque, N·m (n = 88)			Peak VO2, mL/kg/min (n = 67)
Variable	Yes	No	p value	Yes	No	p value
Sex (Yes, male; No, female)	1.65 ± 0.52	1.40 ± 0.37	0.011	19.66 ± 4.17	19.54 ± 4.20	0.905
Leukemia	1.45 ± 0.48	1.67 ± 0.44	0.044	19.55 ± 4.28	19.70 ± 3.97	0.895
Lymphoma	1.60 ± 0.51	1.52 ± 0.47	0.578	18.77 ± 3.27	19.73 ± 4.28	0.522
Multiple myeloma	1.63 ± 0.43	1.51 ± 0.48	0.477	21.20 ± 5.03	19.38 ± 4.02	0.248
Aplastic anemia	1.82 ± 0.33	1.50 ± 0.48	0.065	18.96 ± 3.20	19.65 ± 4.24	0.724
Myeloablative conditioning	1.57 ± 0.48	1.46 ± 0.46	0.311	19.48 ± 4.26	19.85 ± 4.02	0.736
Total body irradiation	1.57 ± 0.48	1.42 ± 0.44	0.216	19.40 ± 4.28	20.14 ± 3.85	0.523
Cytomegalovirus disease	1.37 ± 0.57	1.56 ± 0.45	0.190	19.90 ± 2.37	19.56 ± 4.33	0.841
Bacterial infection	1.49 ± 0.49	1.57 ± 0.45	0.440	19.45 ± 4.08	19.80 ± 4.32	0.735
Invasive pulmonary aspergillosis	1.14 ± 0.45	1.54 ± 0.47	0.145	18.55 ± 2.62	19.63 ± 4.20	0.720

Data are presented as mean ± standard deviation

VO oxygen consumption, HSCT hematopoietic stem cell transplantation

Table 4

Multiple regression analysis of post-hematopoietic stem cell transplantation muscle strength and cardiopulmonary fitness

	Unstandardized coefficient	Standard error	Standardized coefficient	t	p value
A. Model for post-HSCT leg extension torque (n = 88)a
Pre-HSCT leg extension torque	0.601	0.082	0.519	7.345	< 0.001
Grades of acute GVHD	− 0.101	0.032	− 0.222	− 3.143	0.002
Age	− 0.009	0.003	− 0.225	− 2.917	0.005
Pre- and post-evaluation interval	− 0.007	0.002	− 0.229	− 3.241	0.002
Constant	1.405	0.275		5.104	< 0.001
B. Model for post-HSCT peak VO2 (n = 67)b
Pre-HSCT peak VO2	0.457	0.098	0.502	4.684	< 0.001
Constant	9.174	2.269		4.043	< 0.001

HSCT hematopoietic stem cell transplantation, GVHD graft-versus-host disease, VO oxygen consumption

aF (4, 72) = 40.86, p < 0.001, adjusted R2 = 0.677

bF (1, 65) = 21.94, p < 0.001, adjusted R2 = 0.252

Discussion

This study identified the factors associated with post-treatment lower limb muscle strength and cardiopulmonary fitness in 88 patients who underwent allogenic HSCT. Both leg extension torque and peak VO2 significantly reduced after HSCT, and the pre-transplant values of peak VO2 and leg extension torque were significantly related to their respective post-transplant values. Post-HSCT leg extension torque was also significantly associated with grades of acute GVHD, age, and pre- and post-evaluation interval.

The effect of pre-HSCT physical status on post-HSCT status has not been well understood as previous studies did not include pre-transplant physical status into their analyses [17, 18]. Thus, to our knowledge, our study was the first to reveal that post-HSCT leg extension torque and peak VO2 were strongly associated with each of their pre-HSCT variables, respectively. These findings suggest that the higher the physical function before HSCT, the higher the physical function after HSCT. Previous studies showed that physical fitness was lower in patients before HSCT than in healthy subjects [28], and low functional capacity was associated with high mortality [29, 30] and longer hospital stay [30]. Considering these findings and those of the present study, maximizing physical capacity before HSCT could lead to better functional outcomes, as well as reduce the length of hospital stay and mortality risk.

Regarding leg extension torque, a significant negative correlation between the grades of acute GVHD and leg extension torque after HSCT was found. There are two possible reasons for this finding. First, acute GVHD is a significant factor that influences substantial deterioration in nutritional status during HSCT and in the early period after HSCT [31]. Second, it is known that the decrease in strength is associated with total dose of corticosteroids [17, 18]. In general, corticosteroids are administered to patients with grade II or higher GVHD and are often used at lower doses in grade II than in grade III or IV disease [32, 33]. Thus, steroidal muscle atrophy may have been involved in muscle weakness, in addition to exhaustion and malnutrition due to GVHD itself. Considering the relationship between the dose of corticosteroids and the severity of GVHD, our findings are consistent with previous studies that showed a relationship between muscle strength and corticosteroids dose [17, 18]. With regard to age, it has been reported that loss of muscle strength with aging [34-37] may be accelerated by the failure of muscle mass recovery after temporary disuse-induced muscle atrophy [35]. Therefore, the finding that the older the patients were, the poorer the muscle strength recovery was during HSCT is quite reasonable. The most logical answer to the question of why the interval between the evaluations was associated with reduced post-HSCT muscular strength is that the patients with longer evaluation intervals might have been in an unstable condition and stayed in the ward for a longer period to prevent infection; these conditions likely led to lower activity levels and might have weakened muscle strength.

Multiple regression analysis revealed that only pre-HSCT peak VO2 was associated with post-HSCT peak VO2. This indicates that the influence of exercise capacity before HSCT has the strongest effect compared with other factors. A relationship between hemoglobin values and exercise capacity was previously reported in healthy individuals [38, 39] and patients with various pathological conditions [40-43], including those requiring HSCT [18]. Although the findings from these previous studies suggested that hemoglobin level influences fitness level, we showed that the hemoglobin level before HSCT did not influence post-HSCT fitness.

The clinical implication drawn from the study is that maximizing the physical function before the HSCT is the key to preserve the function after the HSCT. Self-administered exercise before, during, and after HSCT was shown to be beneficial [12]. Furthermore, the supervised-individualized exercise before the HSCT was proven to be feasible [44]. The findings of these reports and ours suggest that it may be worth doing physical exercise before HSCT, although a well-designed randomized controlled trial is clearly warranted to ascertain the value of pre-HSCT physical exercise intervention.

There were limitations in this study. The study was conducted at a single facility. Only patients who could be evaluated for leg extension muscle strength and cardiopulmonary fitness using CPX were analyzed; therefore, those in poor general condition were not included. In addition, precise information about the dose of steroids and exercise adherence could not be obtained and were not included in the analyses because of the retrospective nature of the study. A prospective study including patients with various characteristics is necessary to increase the generalizability of our findings.

In conclusion, our findings suggest that improving muscular strength and cardiopulmonary fitness before receiving HSCT is important for maintaining physical function after HSCT treatment. Additionally, we emphasize the importance of commencing rehabilitation earlier before HSCT. Our study also suggests that careful consideration should be paid to lower limb muscle strength, especially in elderly individuals who are developing acute GVHD and those who are staying in a protective environment long-term.